For years, Novartis has been trying to find more consistent ways to quantify whether the treatments it is developing for multiple sclerosis are working, but assessing whether a patient’s symptoms are stabilizing or getting worse is complicated. They have now partnered with Microsoft Research to develop a machine learning system that assess these patients.
Microsoft researchers have long been at the cutting edge of a field called machine learning, which is a branch of artificial intelligence in which systems get better at doing something as they gather more data. Machine learning is ideal for a project like Assess MS because, as the computer vision system captures more recordings of patient movements, it can deliver more consistent results showing the disease’s progression.
In the Assess MS project, Microsoft is using Kinect sensor to record patient movements.
Read about this project in detail here.